Bd reports third quarter fiscal 2023 financial results

Continues strong performance and progress toward achieving bd 2025 strategy; advances innovation pipeline and receives clearance for updated bd alaris™ infusion system revenue of $4.9 billion increased 5.1% as reported and 6.3% on a currency-neutral basis revenue from base business (which excludes covid-only diagnostic testing) grew 6.7% as reported, 7.9% currency-neutral or 6.3% organic gaap and adjusted diluted eps from continuing operations of $1.36 and $2.96, respectively company raises full-year base organic revenue growth guidance; maintains full-year adjusted eps guidance franklin lakes, n.j. , aug. 3, 2023 /prnewswire/ -- bd (becton, dickinson and company) (nyse: bdx), a leading global medical technology company, today announced results for its third quarter of fiscal 2023, which ended june 30, 2023.
BDX Ratings Summary
BDX Quant Ranking